Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial.

Liver Transpl · 2018 · PMC5873437 · PMID 29171941

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

14 In a prior phase 2 study, VTI‐206, C3A cellular therapy did not show survival benefit in end‐stage liver disease but a positive trend toward improved survival in a subset of sAH patients. 15 The VTI‐208 study ( NCT01471028 ) was conducted to evaluate the safety and efficacy of ELAD with respect to overall survival (OS) of subjects with sAH.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.